Verma, S. Et Al. 2024. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet , vol.404, no.10454 , 773-786.

Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Colhoun, H. M., ... Plutzky, J.(2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet , vol.404, no.10454, 773-786.

Verma, Subodh Et Al. "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial," The Lancet , vol.404, no.10454, 773-786, 2024

Verma, Subodh Et Al. "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial." The Lancet , vol.404, no.10454, pp.773-786, 2024

Verma, S. Et Al. (2024) . "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial." The Lancet , vol.404, no.10454, pp.773-786.

@article{article, author={Subodh Verma Et Al. }, title={Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial}, journal={The Lancet}, year=2024, pages={773-786} }